Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal

Cancer Chemother Pharmacol. 1985;15(3):300-2. doi: 10.1007/BF00263905.

Abstract

Fifteen patients with advanced squamous cell carcinoma of the anal canal were treated with a combination of bleomycin, vincristine, and high-dose methotrexate (BOM) with leucovorin rescue. Three out of twelve patients with measurable disease had objective responses of 1, 2, and 5 months. Five of the fifteen patients had severe or life-threatening complications as a result of this treatment regimen. The narrow therapeutic index of the BOM therapy makes it a less than ideal drug combination for the treatment of advanced squamous cell carcinoma of the anal canal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / toxicity*
  • Anus Neoplasms / drug therapy*
  • Anus Neoplasms / pathology
  • Bleomycin / administration & dosage
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Humans
  • Leucovorin / administration & dosage*
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoplasm Metastasis
  • Vincristine / administration & dosage

Substances

  • Bleomycin
  • Vincristine
  • Leucovorin
  • Methotrexate

Supplementary concepts

  • VBM protocol